- Home
- TOMZ vs TPST Comparison
TOMZ vs TPST Comparison
Compare TOMZ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOMZ | TPST |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 13.7M |
| IPO Year | 2009 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TOMZ | TPST |
|---|---|---|
| Price | $1.91 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.2K | ★ 237.3K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,635,927.00 | $295,000.00 |
| Revenue This Year | $111.80 | N/A |
| Revenue Next Year | $52.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.21 | $0.50 |
| 52 Week High | $9.73 | $10.45 |
Technical Indicators
Market Signals| Indicator | TOMZ | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 28.68 |
| Support Level | $1.28 | N/A |
| Resistance Level | $1.95 | $1.24 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 80.24 | 1.83 |
Price Performance
Historical ComparisonAbout TOMZ TOMI Environmental Solutions Inc.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.